Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroblastoma 11Brain Neoplasms 3Recurrence 2Osteosarcoma 2Multiple Myeloma 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Glioma 2Glioblastoma 2Diffuse Intrinsic Pontine Glioma 2Xanthomatosis, Cerebrotendinous 1Vaccinia 1Uveal Melanoma 1Transplant-Related Hematologic Malignancy 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Resectable Esophageal Cancer 1Prostatic Neoplasms 1Pathologic Complete Response 1Oligodendroglioma 1Neoplasms 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liver Neoplasms 1Leukemia 1Kidney Neoplasms 1Influenza, Human 1

Interventions

Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Chemoradiotherapy 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Esophageal Cancer × Granulocyte-Macrophage Colony-Stimulating Factor × 1 year × Clear all
NCT05307835 2025-12-02

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Active not recruiting
27 enrolled
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡